Hvivo (HVO) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Jun 2022 12:00 PM
RNS
Annual Report and Notice of AGM
08 Jun 2022 07:00 AM
RNS
Board appointment
07 Jun 2022 09:05 AM
RNS
Second Price Monitoring Extn
07 Jun 2022 09:00 AM
RNS
Price Monitoring Extension
07 Jun 2022 07:00 AM
RNS
Final results
01 Jun 2022 07:00 AM
RNS
GBP14.7m influenza contract signed
26 May 2022 07:00 AM
RNS
Completion of Nominated Adviser due diligence
24 May 2022 07:00 AM
RNS
Notice of results
18 May 2022 07:00 AM
RNS
£7.3m Influenza human challenge study contract win
12 May 2022 07:00 AM
RNS
Wellcome publication
05 May 2022 07:00 AM
RNS
Vaccine field study contract
04 May 2022 07:00 AM
RNS
Comment re: speculation
04 May 2022 07:00 AM
RNS
Challenge virus manufacturing contract
28 Apr 2022 07:00 AM
RNS
Appointment of Nominated Adviser and Joint Broker
13 Apr 2022 07:00 AM
RNS
Proposal to Distribution in Specie Shareholders
12 Apr 2022 12:00 PM
RNS
Presentation at World Vaccine Congress
06 Apr 2022 04:35 PM
RNS
Price Monitoring Extension
06 Apr 2022 02:05 PM
RNS
Second Price Monitoring Extn
06 Apr 2022 02:01 PM
RNS
Price Monitoring Extension
06 Apr 2022 11:05 AM
RNS
Second Price Monitoring Extn
06 Apr 2022 11:00 AM
RNS
Price Monitoring Extension
31 Mar 2022 10:05 AM
RNS
Characterisation Study results in Nature Medicine
25 Mar 2022 07:00 AM
RNS
£5m RSV human challenge study contract win
09 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
09 Mar 2022 04:37 PM
RNS
Price Monitoring Extension
08 Mar 2022 07:00 AM
RNS
Trading Update and screening facilities expansion
07 Mar 2022 02:06 PM
RNS
Second Price Monitoring Extn
07 Mar 2022 02:00 PM
RNS
Price Monitoring Extension
07 Mar 2022 11:06 AM
RNS
Second Price Monitoring Extn
07 Mar 2022 11:00 AM
RNS
Price Monitoring Extension
02 Mar 2022 07:00 AM
RNS
Investor Presentations
24 Feb 2022 07:00 AM
RNS
CEO Appointment
22 Feb 2022 07:00 AM
RNS
FDA Breakthrough Designation for Big Pharma RSV
17 Feb 2022 12:05 PM
RNS
Positive results from RSV Human Challenge Study
14 Feb 2022 07:00 AM
RNS
Launch of STRiVE project
02 Feb 2022 07:00 AM
RNS
World's first COVID-19 Characterisation Study
26 Jan 2022 04:40 PM
RNS
Second Price Monitoring Extn
26 Jan 2022 04:36 PM
RNS
Price Monitoring Extension
20 Jan 2022 07:00 AM
RNS
Malaria Human Challenge Model Launched
21 Dec 2021 07:00 AM
RNS
£5m Influenza human challenge study contract win
16 Dec 2021 04:41 PM
RNS
Second Price Monitoring Extn
16 Dec 2021 04:35 PM
RNS
Price Monitoring Extension
10 Dec 2021 11:05 AM
RNS
Second Price Monitoring Extn
10 Dec 2021 11:00 AM
RNS
Price Monitoring Extension
10 Dec 2021 07:05 AM
RNS
Exercise of Options
10 Dec 2021 07:00 AM
RNS
$13.4m Influenza HCS contract win
06 Dec 2021 07:00 AM
RNS
Positive results from Flu Human Challenge Study
19 Nov 2021 07:00 AM
RNS
Imutex Vaccine Phase I Study Results
17 Nov 2021 07:00 AM
RNS
£5.1m RSV contract
15 Nov 2021 07:00 AM
RNS
£1.5m Contract renewal for Venn Life Sciences

hVIVO is a contract research organization that conducts human challenge clinical trials for respiratory and infectious disease vaccines and therapeutics:

hVIVO offers services such as challenge trials, assay development, field trial bio-logistics, cell based assays, molecular services, compound efficacy and VRM, and biomarker analysis.

Formerly known as Retroscreen, hVIVO was renamed in 2015 when it went public on the London Stock Exchange.

hVIVO has a portfolio of 11 human challenge models, with more models in development. Their portfolio includes models for influenza, respiratory syncytial virus, human rhinovirus, asthma, COPD, cough, malaria, COVID-19, and hMPV.

hVIVO share price launched at 33p in 2012.

UK 100

Latest directors dealings